Autism Spectrum Disorders: Novel Therapeutics & Neutraceuticals

Last Wednesday, 12/2/15, I had the pleasure of attending a Round Table Discussion entitled Autism Spectrum Disorders: Novel Therapeutics & Neutraceuticals. It was a riveting conversation. Dr. Eric Hollander, director of the Spectrum Neuroscience and Treatment Institute, gave a great presentation. He shared scientific breakthroughs in the world of Autism Spectrum Disorders, including discussing “an innovative non-drug dietary approach for addressing lipid imbalances to manage ADHD symptoms,” called Vayarin. Vayarin is described as “a prescription medical food for use under physician supervision and is intended for the clinical dietary management of ADHD.”

We learned that the Spectrum Neuroscience and Treatment Institute is conducting a Research Study for Children with Autism Spectrum Disorder. The study is sponsored by Enzymotec, the makers of Vayarin.

• Here are some of the requirements for a child to be eligible to participate:
• Be between the ages of 6 and 17
• Meet the criteria for an Autism Spectrum Disorder
• Not have allergies or sensitivity to fish, seafood or soy
• Be stable on their current medications

If anyone is interested in learning more, check out their website: http://www.spectrumneuroscience.com/a-study-of-medical-food-in-children-with-autism-spectrum-disorder-asd/

You can also review http://www.vayarin.com/

In addition, you can get more information about the study, including benefits and risks, by contacting eb*****@******************ce.org or calling 1-646-351-0214